Alexion Pharmaceuticals Inc. | Mutual Funds
Mutual Funds that own Alexion Pharmaceuticals Inc.
Vanguard Total Stock Market Index Fund
5,311,313
2.38%
24,726
0.09%
07/31/2018
T Rowe Price Blue Chip Growth Fund
4,574,250
2.04%
244,400
0.98%
06/30/2018
T Rowe Price Growth Stock Fund
4,189,170
1.88%
-395,636
0.91%
06/30/2018
Vanguard 500 Index Fund
4,028,575
1.81%
5,059
0.11%
07/31/2018
Government Pension Fund - Global (The)
3,432,536
1.54%
1,507,771
0.05%
12/31/2017
iShares Nasdaq Biotechnology ETF
2,572,458
1.14%
-33,642
3.21%
09/06/2018
SPDR S&P 500 ETF
2,456,722
1.1%
28,427
0.11%
09/06/2018
T Rowe Price Health Sciences Fund
2,425,595
1.09%
600,146
2.33%
06/30/2018
Fidelity Select Biotechnology Portfolio
2,372,060
1.06%
234,031
3.16%
07/31/2018
Vanguard Institutional Index Fund
2,152,549
0.97%
2,301
0.11%
07/31/2018
| Address |
121 Seaport Boulevard
Boston Massachusetts 02210
United States
|
|
Employees
|
- |
| Website |
http://www.alexion.com |
| Updated |
07/08/2019 |
| Alexion Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Its products include soliris, strensiq and kanuma. The company was founded by Joseph A. |
